Cargando…
Retargeting the management of hypercholesterolemia – focus on evolocumab
Hypercholesterolemia is one of the main risk factors for atherosclerosis and cardiovascular diseases. The treatment is based on the modification of the diet and lifestyle and if necessary on a pharmacological therapy. The most widely used drugs are the inhibitors of 3-hydroxy-3-methyl-glutaryl coenz...
Autores principales: | Colletti, Alessandro, Derosa, Giuseppe, Cicero, Arrigo FG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019477/ https://www.ncbi.nlm.nih.gov/pubmed/27660454 http://dx.doi.org/10.2147/TCRM.S116679 |
Ejemplares similares
-
Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015) -
Short-term evolocumab-induced tendon xanthomas regression in an elderly patient with homozygous familial hypercholesterolemia
por: Cicero, Arrigo F. G., et al.
Publicado: (2022) -
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2018) -
Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019) -
Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
por: Huang, Chin-Chou, et al.
Publicado: (2019)